Atlas Trials

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

Clinical trial NCT04507906 · COMPLETED

Trial details

NCT number
NCT04507906
Sponsor
Shanghai Chest Hospital
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
NSCLC Stage IVCheckpoint Inhibitor
Start date
2020-11-02
Primary completion
2022-03-31
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.